Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 9 min ago
Peer-reviewedCC BYRheumatology and immunology research

Chinese expert consensus on the treatment of immune‑mediated inflammatory diseases with Janus kinase inhibitors.

  • Xiaofeng Zeng1
  • Jianzhong Zhang2
  • Minhu Chen3
  • National Clinical Research Center for Rheumatic and Autoimmune Diseases (Peking Union Medical College Hospital), Chinese Association of Rheumatology and Immunology PhysiciansDermatology Professional Committee of Chinese Rehabilitation Medical Association
  1. 1Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
  2. 2Department of Dermatology, Peking University People's Hospital, Beijing, China.
  3. 3Department of Gastroenterology, the First Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong Province, China.
Read full textPDFDOICite

Abstract

In recent years, Janus kinase (JAK) inhibitors have been approved for the treatment of various immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, juvenile idiopathic arthritis, giant cell arteritis, atopic dermatitis, alopecia areata, psoriasis, and inflammatory bowel disease. To standardize the clinical application of JAK inhibitors for IMIDs in China, this consensus group has developed the "Chinese Expert Consensus on the Treatment of Immune-Mediated Inflammatory Diseases with Janus Kinase Inhibitors." This consensus is formulated based on relevant evidence-based medicine, the latest research data from both domestic and international studies, and the clinical experience of the expert panel. It covers key aspects such as treatment protocols, safety management, and medication use in special patient populations. The aim of this consensus is to assist physicians in making rational clinical decisions regarding the use of JAK inhibitors.

Related

  1. Interpreting the Early Cancer Peak in Immune-Mediated Inflammatory Diseases. Comment on Giordani et al. Cancer Association in Patients with Immune-Mediated Inflammatory Diseases: A Five-Year Nationwide Italian Cohort Study. Cancers 2026, 18, 1027
    Alper Gumustepe, Esra Gumustepe
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  2. COVID-19 severity and early inflammatory biomarkers in patients with immune-mediated inflammatory rheumatic diseases: a multicenter cohort study
    Andreea-Iulia Vlădulescu-Trandafir, Gelu Onose, Violeta-Claudia Bojincă +5
    Journal of medicine and lifePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Reply to Gumustepe, A.; Gumustepe, E. Comment on “Giordani et al. Cancer Association in Patients with Immune-Mediated Inflammatory Diseases: A Five-Year Nationwide Italian Cohort Study. Cancers 2026, 18, 3449”
    Barbara Giordani, Luigi Pirtoli, Guido Putignano +3
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  4. Bruton Tyrosine Kinase Inhibitors in Immune-Mediated Skin Diseases: Current Evidence and Future Directions
    Zihan Wang, Junchen He, Ting Zhang +6
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  5. Uncovering combination therapies for immune-mediated inflammatory diseases through systems biology analysis on longitudinal patient data
    Sergio H. Martínez-Mateu, Yolanda Guillén, Edgar Angelats +23
    Cell Reports MedicinePeer-reviewedCC BY 4.0Full textGeneral medicinePMC

Cite

BibTeXRIS
BibTeX
@article{zeng2026chinese,
  title = {{Chinese expert consensus on the treatment of immune‑mediated inflammatory diseases with Janus kinase inhibitors.}},
  author = {Xiaofeng Zeng and Jianzhong Zhang and Minhu Chen and National Clinical Research Center for Rheumatic and Autoimmune Diseases (Peking Union Medical College Hospital), Chinese Association of Rheumatology and Immunology PhysiciansDermatology Professional Committee of Chinese Rehabilitation Medical Association},
  journal = {Rheumatology and immunology research},
  year = {2026},
  month = oct,
  doi = {10.1515/rir-2026-0028},
  url = {https://europepmc.org/article/MED/42923801},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Chinese expert consensus on the treatment of immune‑mediated inflammatory diseases with Janus kinase inhibitors.
AU  - Xiaofeng Zeng
AU  - Jianzhong Zhang
AU  - Minhu Chen
AU  - National Clinical Research Center for Rheumatic and Autoimmune Diseases (Peking Union Medical College Hospital), Chinese Association of Rheumatology and Immunology PhysiciansDermatology Professional Committee of Chinese Rehabilitation Medical Association
PY  - 2026
DA  - 2026/10/22
JO  - Rheumatology and immunology research
DO  - 10.1515/rir-2026-0028
UR  - https://europepmc.org/article/MED/42923801
AB  - In recent years, Janus kinase (JAK) inhibitors have been approved for the treatment of various immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, juvenile idiopathic arthritis, giant cell arteritis, atopic dermatitis, alopecia areata, psoriasis, and inflammatory bowel disease. To standardize the clinical application of JAK inhibitors for IMIDs in China, this consensus group has developed the "Chinese Expert Consensus on the Treatment of Immune-Mediated Inflammatory Diseases with Janus Kinase Inhibitors." This consensus is formulated based on relevant evidence-based medicine, the latest research data from both domestic and international studies, and the clinical experience of the expert panel. It covers key aspects such as treatment protocols, safety management, and medication use in special patient populations. The aim of this consensus is to assist physicians in making rational clinical decisions regarding the use of JAK inhibitors.
SN  - 2719-4523
ER  -